An innovative life sciences platform
transforming the future of healthcare

LifeSci Acquisition II Corporation, a Special Purpose Acquisition Company, Sponsored by an Affiliate of LifeSci Partners, Announces the Acquisition of Science 37, Inc.

View Our Prospectus

Management Team

Andrew McDonald
Chief Executive Officer

Andrew McDonald

Chief Executive Officer 

Andrew is an experienced healthcare investment professional with expertise identifying transformative products and technologies in all stages of development. Andrew is a Founding Partner of LifeSci Advisors and LifeSci Captial. Prior to founding LifeSci, Andrew serves as senior biotechnology analyst at Great Point Partners, a dedicated life science hedge fund. From 2004 – 2006 Andrew was Head of Healthcare Research and a Biotechnology Analyst at ThinkEquity Partners, a boutique investment bank. Prior to entering the financial services industry, Andrew was a medicinal chemist at Cytokinetics from 2001 – 2004, where he discovered and developed a promising anti-cancer agent now in clinical trials. Andrew began his pharmaceutical career as a medicinal chemist at Pfizer. Andrew received a Ph.D. in organic chemistry from UC Irvine and completed his B.S. in chemistry at U.C. Berkley. Andrew holds the Series 7, 24, 63, 79, 86, and 87.

Michael Rice
Chief Operating Officer

Michael Rice

Chief Operating Officer
Michael has experience in portfolio management, corporate management, investment banking and capital markets. Prior to co-founding LifeSci Advisors and LifeSci Capital, Michael was the co-head of health care investment banking at Canaccord Adams, where he was involved in debt and equity financing. Michael was also was a Managing Director at Think Equity Partners where he was responsible for managing Healthcare Capital Markets, which included structuring and executing numerous transactions, many of which were firsts at ThinkEquity. Prior to that, Michael served as a Managing Director at Banc of America serving large hedge funds and private equity healthcare funds. Previously, he was a Managing Director at JPMorgan/Hambrecht & Quist.
David Dobkin
Chief Financial Officer

David Dobkin

Chief Financial Officer

David is an experienced healthcare capital markets investment banker with a career focused on helping high-growth life science, medical device, and healthcare IT companies achieve their financial and strategic goals. Prior to joining LifeSci Capital, David founded Dobkin & Company, an investment bank tailored for entrepreneur-lead companies focused on seed and growth equity and capital. Previously, David worked in various capacities with the New Zealand Government facilitating capital formation on behalf of regional companies and government agencies with a focus on securing strategic foreign direct investment. David has tremendous experience conducting cross-border transactions. Prior to October 2010, David worked for Lazard Frères, one of the world’s preeminent financial advisory and asset management firms, where he facilitated and advised on cross-border mergers and acquisitions transactions in excess of $3 billion. Prior to joining for Lazard Frères, David began his career in in the Healthcare investment banking group for Wasserstein Perella based in New York. David conducted graduate research in stem cell bio-engineering and received a Master of Science, Biomedical Engineering, from the University of Southern California. David also received a Bachelor of Science, Biomedical Engineering, from Columbia University. David holds the Series 63, 79, and 82.

Matthew Margiotta
Vice President

Matthew Margiotta

Vice President

Matthew joined LifeSci Capital in 2018 as a member of the investment banking team, where he has advised on capital markets and M&A transactions for promising early-stage biotech and medtech, behavioral health, and healthcare technology companies. Prior to joining LifeSci, Matthew spent time at Bank of America Merrill Lynch and UBS in their Global Wealth & Investment Management divisions, with a focus on biotech equity research. Matthew graduated from the University of Michigan and received his B.S. with majors in Mathematics and Statistics. 

Bob Spivak
Vice President

Bob Spivak

Vice President

Bob joined LifeSci Capital in 2018 as a member of the investment banking team, where he advises on both capital markets and M&A transactions for biotech, medtech, healthcare services and healthcare technology companies. Bob is also the Vice President of LifeSci Acquisition and LifeSci Acquisition II, where he assists in identifying a strong target to acquire into LifeSci’s special purpose acquisition company. Prior to joining LifeSci, Bob spent his time at Maxim Group in their investment banking division. Bob graduated from Pace University and received a BBA with majors in Finance and Mathematics.

Board of Directors

• Thomas Wynn

Thomas Wynn

Thomas, who will become our Board Member at the closing of this offering, has been a portfolio manager at Monashee Investment Management since 2011. From 1995 to 2011, he co-founded and served as the Managing Director of Leerink Swann LLC, a Boston based healthcare investment bank. From 1991 to 1995, he worked at Lehman Brothers. Thomas received his B.A from Fairfield University and J.D. from Suffolk University We believe Thomas is qualified to sit on our board due to long-running experience in healthcare investing and advisory services.

• Thomas Mathers

Thomas Mathers

Thomas will become our Board Member at the closing of this offering, founded and has been the President and CEO at Allievex Corporation, a company neurodegenerative diseases, since April 2018. He has also been a General Partner at Pappas Ventures V, a venture capital company, since February 2018. Prior to Pappas Capital and Allievex, from June 2010 to March 2017, Tom was the President and CEO of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD), a biotechnology company founded by Pappas Capital, which focused on the development of lasmiditan for the acute treatment of migraine headaches. Eli Lilly & Company acquired CoLucid in March 2017 in an all cash transaction for nearly $1 billion. Prior to CoLucid, he was President and CEO of Peptimmune, Inc.; President and CEO of Cell Based Delivery, Inc; Vice President and General Manager of Cardion AG; and Vice President of Strategic Development at Genzyme Corporation. Tom currently serves as a Trustee of Butler University and is co-founder and Chairman of Déclion Holdings, a biopharmaceutical company focused on the discovery and development of innovative treatments for neurodegenerative diseases. He is also a business advisor to the Progeria Research Foundation, and previously served on the Board of Directors for the Biotechnology Industry Organization for nine years, where he was active in the policy areas of capital formation, bioethics, intellectual property, and regulatory policy. From 1988 to 1991, Tom served as a captain in the United States Army and was awarded several medals for his services as an AH-64 Apache helicopter pilot in the Gulf War. We believe Thomas is qualified to sit on our board due to his long-running experience in early stage investing and experience on company boards.

• Graham Walmsley

Graham Walmsley

Graham will become our Board Member at the closing of this offering, has been the General Partner of Logos Global Management, LP, a biotechnology-focused investment partnership based in San Francisco, since August 2019. He was a principal at Versant Ventures, a leading healthcare investment firm, from July 2016 until August 2019. He was the Head of Business Development at Jecure Therapeutics, a developer of therapeutics targeting non-alcoholic steatohepatitis and liver fibrosis from June 2017 until March 2019. From July 2012 to June 2016 he was an Affiliated Trainee at Stanford Hospital & Clinics. He is currently a member of the Board of Directors of ALX Oncology (NASDAQ: ALXO), Olema Pharmaceuticals (NASDAQ: OLMA), and Akero Therapeutics (NASDAQ: AKRO). We believe Graham is qualified to sit on our board due to his extensive experience in biotechnology investing and previous company board positions.

• Scott Janssen

Scott Janssen

Scott will become our Board Member at the closing of this offering, was the Chief Accounting Officer at CMG Partners from August 2019 to April 2020. Scott has over 25 years of accounting, finance and operational experience working within and consulting to public and private companies within the life science and technology space. Scott was a Managing Director of the Connor Group from January 2014 to August 2019 to where he supported his clients by providing them accounting and operational consulting services. Mr. Janssen spent six years of his career from January 1993 to November 1999 as an auditor with Ernst & Young and Grant Thornton in the Bay Area and Los Angeles. He was a Managing Director at Connor Group, a consulting firm from January 2014 to August 2019. Scott received a B.S. in Applied Mathematics from the University of California, Los Angeles. We believe Scott is qualified to sit on our board due to his long-running experience in accounting and finance consulting roles.

• Elizabeth Barrett

Elizabeth Barrett

Elizabeth, who will become our Board Member on the effective date of the registration statement of which this prospectus is a part, is a highly regarded industry leader with extensive experience leading business organizations and Fortune 500 pharmaceutical companies. Since January 2019, Liz has served as President and CEOof UroGen Pharma. Prior to UroGen, from February 2018 to January 2019, Liz was CEO of Novartis Oncology and a member of the Novartis Executive Committee. She previously was previously at Pfizer Inc. from March 2009 to January 2019, where she held numerous leadership positions, including Global President of Oncology, President of Global Innovative Pharma for Europe, President of the Specialty Care Business Unit for North America, and President of United States Oncology. Prior to Pfizer, Liz held positions at Cephalon Inc., where she was Vice President and General Manager of the Oncology Business Unit, and at Johnson & Johnson. She started her career at Kraft Foods Group, Inc. Liz received a B.A. from the University of Louisiana and an M.B.A. from Saint Joseph’s University.

About Science37

To learn more about Science37, please visit science37.com/

Press Release

Science 37 to Become Publicly Listed via Merger with LifeSci Acquisition II Corp., Powering the Clinical Trial Operating System of the Future

Presentations

Corporate Overview

Investors

NASDAQ: LSAQ


SEC PROSPECTUS (424B4)

Contact

250 West 55th St. 
Suite 3401 
New York, NY 10019

investment@lifesciacquisition.com 

© 2020 LifeSci Acquisition II Corp. All rights reserved.    Privacy Policy